$ABEO News

Abeona Therapeutics 13D Filing Shows James Russell Revocable Trust Raises Stake In Co To 6.1% As Of October 15, 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone

Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...

ABEO: Zevaskyn® Launch Gains Momentum

Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary

Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity

Abeona Therapeutics Q2 Earnings Call Highlights

Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

Abeona Therapeutics Q2 2026 Earnings Call Transcript